Hussman Strategic Advisors Inc. Purchases Shares of 10,500 The Clorox Company (NYSE:CLX)

Hussman Strategic Advisors Inc. acquired a new stake in The Clorox Company (NYSE:CLX - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 10,500 shares of the company's stock, valued at approximately $1,546,000.

A number of other large investors have also recently made changes to their positions in the business. Sonora Investment Management Group LLC lifted its position in shares of Clorox by 2.5% during the first quarter. Sonora Investment Management Group LLC now owns 2,940 shares of the company's stock valued at $433,000 after purchasing an additional 72 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in shares of Clorox by 0.6% during the first quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 13,266 shares of the company's stock valued at $1,953,000 after purchasing an additional 73 shares in the last quarter. Wedbush Securities Inc. increased its holdings in Clorox by 1.2% during the fourth quarter. Wedbush Securities Inc. now owns 7,624 shares of the company's stock worth $1,238,000 after buying an additional 94 shares during the last quarter. Blair William & Co. IL increased its holdings in Clorox by 1.2% during the fourth quarter. Blair William & Co. IL now owns 9,271 shares of the company's stock worth $1,506,000 after buying an additional 107 shares during the last quarter. Finally, Financial Avengers Inc. increased its stake in shares of Clorox by 32.1% in the fourth quarter. Financial Avengers Inc. now owns 457 shares of the company's stock worth $74,000 after purchasing an additional 111 shares in the last quarter. 78.53% of the stock is owned by institutional investors.

Clorox Trading Down 0.8%

CLX stock traded down $0.98 during mid-day trading on Friday, reaching $128.28. 1,662,271 shares of the stock traded hands, compared to its average volume of 1,426,918. The company has a debt-to-equity ratio of 13.07, a quick ratio of 0.44 and a current ratio of 0.74. The Clorox Company has a one year low of $117.35 and a one year high of $171.37. The stock has a market capitalization of $15.81 billion, a PE ratio of 23.03, a PEG ratio of 3.39 and a beta of 0.51. The business has a 50-day moving average price of $127.36 and a two-hundred day moving average price of $141.35.

Clorox (NYSE:CLX - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). Clorox had a net margin of 9.89% and a return on equity of 324.23%. The company had revenue of $1.67 billion for the quarter, compared to analysts' expectations of $1.74 billion. During the same period in the prior year, the firm posted $1.71 earnings per share. The firm's revenue for the quarter was down 8.0% compared to the same quarter last year. Equities research analysts expect that The Clorox Company will post 7.15 EPS for the current year.

Insider Activity

In related news, Director Pierre R. Breber bought 4,000 shares of the stock in a transaction that occurred on Wednesday, May 7th. The stock was bought at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the purchase, the director directly owned 4,000 shares of the company's stock, valued at approximately $546,280. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.57% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on CLX. Evercore ISI set a $140.00 price objective on shares of Clorox and gave the company an "underperform" rating in a research note on Tuesday, May 6th. Citigroup reissued a "neutral" rating and set a $135.00 price target (down previously from $140.00) on shares of Clorox in a research report on Tuesday. Wells Fargo & Company decreased their price objective on shares of Clorox from $142.00 to $135.00 and set an "equal weight" rating for the company in a report on Wednesday, July 9th. Jefferies Financial Group dropped their target price on shares of Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. Finally, UBS Group lowered their price target on shares of Clorox from $150.00 to $134.00 and set a "neutral" rating for the company in a research report on Thursday. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $145.17.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.